Literature DB >> 2601725

A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes.

N H Choi1, T Mazda, M Tomita.   

Abstract

SP40,40 was isolated from the soluble membrane attack complex (SC5b-9) by HPLC using a reverse-phase column. Amino acid compositions of its alpha- and beta-subunits were similar to each other with the exception of glycine content. Amino-terminal sequences of its alpha- and beta-subunits were identical to those of the subunits prepared from human serum, respectively, indicating that there was no degradation of SP40,40 during incorporation into SC5b-9. When guinea pig erythrocytes were incubated with C56f, C7, C8 and C9 in the presence of SP40,40, SP40,40 enhanced the hemolysis. The protein, however, inhibited the hemolysis when erythrocytes were pre-incubated with C56f and SP40,40 prior to the addition of C7, C8 and C9. These findings indicate that SP40,40 modulates the formation of membrane attack complex by interacting with C56f at the first step, and that the co-existence of other factors, besides C56f, is required for the enhancing activity of SP40,40.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2601725     DOI: 10.1016/0161-5890(89)90139-9

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  30 in total

1.  Overexpression of clusterin in human breast carcinoma.

Authors:  M Redondo; E Villar; J Torres-Muñoz; T Tellez; M Morell; C K Petito
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  SP-40,40 is a constituent of Alzheimer's amyloid.

Authors:  N H Choi-Miura; Y Ihara; K Fukuchi; M Takeda; Y Nakano; T Tobe; M Tomita
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells.

Authors:  Chung Hee Sonn; Young-Bin Yu; Young-Joo Hong; Young-Jun Shim; Jeffrey A Bluestone; Bon-Hong Min; Kyung-Mi Lee
Journal:  J Leukoc Biol       Date:  2010-08-20       Impact factor: 4.962

4.  Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

Authors:  T Mitsuhashi; Y M Li; S Fishbane; H Vlassara
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 5.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

6.  Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation.

Authors:  Shinwu Jeong; Dolena R Ledee; Gabriel M Gordon; Tatsuo Itakura; Nitin Patel; Aaron Martin; M Elizabeth Fini
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

Review 7.  Complement in human reproduction: activation and control.

Authors:  I A Rooney; T J Oglesby; J P Atkinson
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

8.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.

Authors:  J Ghiso; E Matsubara; A Koudinov; N H Choi-Miura; M Tomita; T Wisniewski; B Frangione
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

9.  Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death.

Authors:  M Danik; J G Chabot; C Mercier; A L Benabid; C Chauvin; R Quirion; M Suh
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 10.  Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.

Authors:  Peng Xiu; Xiao-Feng Dong; Xin-Ping Li; Jie Li
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.